Is STEX or SGP more profitable?

Spyglass Pharma's return on equity of 0.00% beat Biosig Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Biosig Technologies N/A -717.92% -336.75% Spyglass Pharma N/A N/A N/A

Does the media refer more to STEX or SGP?

In the previous week, Biosig Technologies and Biosig Technologies both had 6 articles in the media. Biosig Technologies' average media sentiment score of 0.40 beat Spyglass Pharma's score of -0.10 indicating that Biosig Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biosig Technologies 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to STEX or MDXG?

In the previous week, Biosig Technologies had 3 more articles in the media than MiMedx Group. MarketBeat recorded 6 mentions for Biosig Technologies and 3 mentions for MiMedx Group. Biosig Technologies' average media sentiment score of 0.40 beat MiMedx Group's score of 0.22 indicating that Biosig Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biosig Technologies 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiMedx Group 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer STEX or BWAY?

In the previous week, Brainsway had 2 more articles in the media than Biosig Technologies. MarketBeat recorded 8 mentions for Brainsway and 6 mentions for Biosig Technologies. Brainsway's average media sentiment score of 0.67 beat Biosig Technologies' score of 0.40 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biosig Technologies 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Brainsway 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Biosig Technologies (STEX) Competitors

$0.76 -0.05 (-5.88%)

Closing price 04:00 PM Eastern

Extended Trading

$0.78 +0.02 (+2.30%)

As of 07:54 PM Eastern

Compare

STEX vs. SGP, MDXG, BWAY, NPCE, and CLPT

Should you buy Biosig Technologies stock or one of its competitors? MarketBeat compares Biosig Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biosig Technologies include Spyglass Pharma (SGP), MiMedx Group (MDXG), Brainsway (BWAY), NeuroPace (NPCE), and ClearPoint Neuro (CLPT). These companies are all part of the "medical equipment" industry.

How does Biosig Technologies compare to Spyglass Pharma?

Biosig Technologies (NASDAQ:STEX) and Spyglass Pharma (NASDAQ:SGP) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Spyglass Pharma's return on equity of 0.00% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
Spyglass Pharma	N/A	N/A	N/A

Spyglass Pharma has lower revenue, but higher earnings than Biosig Technologies. Spyglass Pharma is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	3,461.02	-$462.77M	-$9.71	N/A
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A

In the previous week, Biosig Technologies and Biosig Technologies both had 6 articles in the media. Biosig Technologies' average media sentiment score of 0.40 beat Spyglass Pharma's score of -0.10 indicating that Biosig Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.2% of Biosig Technologies shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Biosig Technologies currently has a consensus target price of $8.00, indicating a potential upside of 950.56%. Spyglass Pharma has a consensus target price of $45.00, indicating a potential upside of 119.08%. Given Biosig Technologies' higher probable upside, analysts plainly believe Biosig Technologies is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Biosig Technologies beats Spyglass Pharma on 6 of the 11 factors compared between the two stocks.

How does Biosig Technologies compare to MiMedx Group?

Biosig Technologies (NASDAQ:STEX) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Biosig Technologies has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

7.2% of Biosig Technologies shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 52.7% of Biosig Technologies shares are held by company insiders. Comparatively, 2.5% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

MiMedx Group has a net margin of 7.88% compared to Biosig Technologies' net margin of 0.00%. MiMedx Group's return on equity of 21.03% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
MiMedx Group	7.88%	21.03%	15.92%

MiMedx Group has higher revenue and earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	3,461.02	-$462.77M	-$9.71	N/A
MiMedx Group	$418.63M	1.48	$48.58M	$0.20	20.85

Biosig Technologies presently has a consensus target price of $8.00, indicating a potential upside of 950.56%. MiMedx Group has a consensus target price of $8.50, indicating a potential upside of 103.84%. Given Biosig Technologies' higher probable upside, research analysts clearly believe Biosig Technologies is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Biosig Technologies had 3 more articles in the media than MiMedx Group. MarketBeat recorded 6 mentions for Biosig Technologies and 3 mentions for MiMedx Group. Biosig Technologies' average media sentiment score of 0.40 beat MiMedx Group's score of 0.22 indicating that Biosig Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiMedx Group	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MiMedx Group beats Biosig Technologies on 10 of the 16 factors compared between the two stocks.

How does Biosig Technologies compare to Brainsway?

Biosig Technologies (NASDAQ:STEX) and Brainsway (NASDAQ:BWAY) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Biosig Technologies has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by insiders. Comparatively, 19.0% of Brainsway shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Brainsway has a net margin of 15.68% compared to Biosig Technologies' net margin of 0.00%. Brainsway's return on equity of 12.28% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
Brainsway	15.68%	12.28%	7.75%

Brainsway has higher revenue and earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	3,461.02	-$462.77M	-$9.71	N/A
Brainsway	$52.22M	12.73	$7.57M	$0.35	47.31

In the previous week, Brainsway had 2 more articles in the media than Biosig Technologies. MarketBeat recorded 8 mentions for Brainsway and 6 mentions for Biosig Technologies. Brainsway's average media sentiment score of 0.67 beat Biosig Technologies' score of 0.40 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainsway	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biosig Technologies presently has a consensus price target of $8.00, indicating a potential upside of 950.56%. Brainsway has a consensus price target of $15.67, indicating a potential downside of 5.39%. Given Biosig Technologies' higher possible upside, equities analysts plainly believe Biosig Technologies is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Brainsway	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

Summary

Brainsway beats Biosig Technologies on 13 of the 17 factors compared between the two stocks.

How does Biosig Technologies compare to NeuroPace?

Biosig Technologies (NASDAQ:STEX) and NeuroPace (NASDAQ:NPCE) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Biosig Technologies presently has a consensus target price of $8.00, indicating a potential upside of 950.56%. NeuroPace has a consensus target price of $18.83, indicating a potential upside of 29.17%. Given Biosig Technologies' higher possible upside, equities analysts plainly believe Biosig Technologies is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

NeuroPace has higher revenue and earnings than Biosig Technologies. NeuroPace is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	3,461.02	-$462.77M	-$9.71	N/A
NeuroPace	$99.99M	4.97	-$21.47M	-$0.65	N/A

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Comparatively, 19.2% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Biosig Technologies has a net margin of 0.00% compared to NeuroPace's net margin of -21.67%. NeuroPace's return on equity of -108.20% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
NeuroPace	-21.67%	-108.20%	-18.50%

Biosig Technologies has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market. Comparatively, NeuroPace has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market.

In the previous week, Biosig Technologies had 6 more articles in the media than NeuroPace. MarketBeat recorded 6 mentions for Biosig Technologies and 0 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.00 beat Biosig Technologies' score of 0.40 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Overall Sentiment
Biosig Technologies	Neutral
NeuroPace	Positive

Summary

NeuroPace beats Biosig Technologies on 10 of the 17 factors compared between the two stocks.

How does Biosig Technologies compare to ClearPoint Neuro?

Biosig Technologies (NASDAQ:STEX) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Biosig Technologies has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

Biosig Technologies currently has a consensus price target of $8.00, indicating a potential upside of 950.56%. ClearPoint Neuro has a consensus price target of $23.00, indicating a potential upside of 53.03%. Given Biosig Technologies' higher probable upside, equities research analysts clearly believe Biosig Technologies is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

ClearPoint Neuro has higher revenue and earnings than Biosig Technologies. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	3,461.02	-$462.77M	-$9.71	N/A
ClearPoint Neuro	$36.97M	12.19	-$25.54M	-$1.01	N/A

Biosig Technologies has a net margin of 0.00% compared to ClearPoint Neuro's net margin of -71.57%. ClearPoint Neuro's return on equity of -140.96% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Biosig Technologies had 6 more articles in the media than ClearPoint Neuro. MarketBeat recorded 6 mentions for Biosig Technologies and 0 mentions for ClearPoint Neuro. Biosig Technologies' average media sentiment score of 0.40 beat ClearPoint Neuro's score of 0.00 indicating that Biosig Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Biosig Technologies	Neutral
ClearPoint Neuro	Neutral

Summary

Biosig Technologies and ClearPoint Neuro tied by winning 8 of the 16 factors compared between the two stocks.

Get Biosig Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STEX vs. The Competition

Export

Metric	Biosig Technologies	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$147.10M	$3.13B	$8.16B	$12.68B
Dividend Yield	N/A	N/A	38.39%	9.42%
P/E Ratio	-0.08	20.65	23.59	23.95
Price / Sales	3,461.02	245.69	134.93	93.75
Price / Cash	N/A	8.89	165.13	60.45
Price / Book	0.92	5.44	13.19	6.16
Net Income	-$462.77M	$23.43M	$120.21M	$331.73M
7 Day Performance	-5.58%	-5.09%	-1.10%	-1.96%
1 Month Performance	-10.41%	-8.46%	-2.48%	-2.49%
1 Year Performance	N/A	1.63%	10.49%	17.21%

Biosig Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STEX Biosig Technologies	3.1565 of 5 stars	$0.76 -5.9%	$8.00 +950.6%	N/A	$147.10M	$40K	N/A	50
SGP Spyglass Pharma	1.7177 of 5 stars	$19.90 -11.6%	$45.00 +126.1%	N/A	$665.32M	N/A	N/A	65
MDXG MiMedx Group	3.1509 of 5 stars	$4.08 -0.7%	$8.50 +108.3%	-35.0%	$612.17M	$418.63M	20.40	870	News Coverage Positive News Upcoming Earnings
BWAY Brainsway	2.5272 of 5 stars	$14.10 -6.4%	$16.00 +13.5%	+167.2%	$604.35M	$52.22M	40.29	120	Analyst Forecast Gap Down
NPCE NeuroPace	3.0995 of 5 stars	$17.12 +0.1%	$18.83 +10.0%	+65.2%	$583.34M	$99.99M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STEX) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biosig Technologies (STEX) Competitors

STEX vs. SGP, MDXG, BWAY, NPCE, and CLPT

How does Biosig Technologies compare to Spyglass Pharma?

Summary

How does Biosig Technologies compare to MiMedx Group?

Summary

How does Biosig Technologies compare to Brainsway?

Summary

How does Biosig Technologies compare to NeuroPace?

Summary

How does Biosig Technologies compare to ClearPoint Neuro?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STEX vs. The Competition

Biosig Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biosig Technologies (STEX) Competitors

STEX vs. SGP, MDXG, BWAY, NPCE, and CLPT

How does Biosig Technologies compare to Spyglass Pharma?

Is STEX or SGP more profitable?

Which has stronger earnings & valuation, STEX or SGP?

Does the media refer more to STEX or SGP?

Do institutionals and insiders believe in STEX or SGP?

Do analysts prefer STEX or SGP?

Summary

How does Biosig Technologies compare to MiMedx Group?

Which has more risk & volatility, STEX or MDXG?

Do insiders & institutionals have more ownership in STEX or MDXG?

Is STEX or MDXG more profitable?

Which has stronger valuation and earnings, STEX or MDXG?

Do analysts prefer STEX or MDXG?

Does the media refer more to STEX or MDXG?

Summary

How does Biosig Technologies compare to Brainsway?

Which has more volatility and risk, STEX or BWAY?

Do institutionals and insiders have more ownership in STEX or BWAY?

Is STEX or BWAY more profitable?

Which has higher earnings and valuation, STEX or BWAY?

Does the media prefer STEX or BWAY?

Do analysts recommend STEX or BWAY?

Summary

How does Biosig Technologies compare to NeuroPace?

Do analysts prefer STEX or NPCE?

Which has higher valuation & earnings, STEX or NPCE?

Do institutionals & insiders have more ownership in STEX or NPCE?

Is STEX or NPCE more profitable?

Which has more risk and volatility, STEX or NPCE?

Does the media prefer STEX or NPCE?

Summary

How does Biosig Technologies compare to ClearPoint Neuro?

Which has more risk & volatility, STEX or CLPT?

Do analysts rate STEX or CLPT?

Which has stronger earnings and valuation, STEX or CLPT?

Is STEX or CLPT more profitable?

Do insiders & institutionals have more ownership in STEX or CLPT?

Does the media prefer STEX or CLPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STEX vs. The Competition

Biosig Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools